William R Ewing

List of Publications by Year
in descending order

65 papers	2,885 citations	159358 30 h-index	182168 51 g-index
65 all docs	65 docs citations	65 times ranked	3104 citing authors

#	Article	IF	Citations
1	Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. Journal of Medicinal Chemistry, 2022, 65, 1770-1785.	2.9	42
2	Milvexian, an orally bioavailable, smallâ€molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits. Journal of Thrombosis and Haemostasis, 2022, 20, 399-408.	1.9	31
3	Site-selective tyrosine bioconjugation via photoredox catalysis for native-to-bioorthogonal protein transformation. Nature Chemistry, 2021, 13, 902-908.	6.6	74
4	A tautomeric ligand enables directed Câ€'H hydroxylation with molecular oxygen. Science, 2021, 372, 1452-1457.	6.0	84
5	Preclinical metabolism and disposition of an orally bioavailable macrocyclic FXIa inhibitor. Xenobiotica, 2021, 51, 933-948.	0.5	2
6	Ligand Enabled Pd(II)-Catalyzed Î³-C(sp³)â€"H Lactamization of Native Amides. Journal of the American Chemical Society, 2021, 143, 21657-21666.	6.6	23
7	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups. Journal of Medicinal Chemistry, 2020, 63, 784-803.	2.9	16
8	Writing Your Next Medicinal Chemistry Article: Journal Bibliometrics and Guiding Principles for Industrial Authors. Journal of Medicinal Chemistry, 2020, 63, 14336-14356.	2.9	5
9	Site-Selective Functionalization of Methionine Residues via Photoredox Catalysis. Journal of the American Chemical Society, 2020, 142, 21260-21266.	6.6	82
10	Nucleophilic (Radio)Fluorination of Redox-Active Esters via Radical-Polar Crossover Enabled by Photoredox Catalysis. Journal of the American Chemical Society, 2020, 142, 9493-9500.	6.6	110
11	Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species. Journal of Medicinal Chemistry, 2020, 63, 7226-7242.	2.9	16
12	Pd^{II}â€Catalyzed Enantioselective C(sp³)â€"H Arylation of Cyclobutyl Ketones Using a Chiral Transient Directing Group. Angewandte Chemie - International Edition, 2020, 59, 9594-9600.	7.2	74
13	Pd II â€Catalyzed Enantioselective C(sp 3)â€"H Arylation of Cyclobutyl Ketones Using a Chiral Transient Directing Group. Angewandte Chemie, 2020, 132, 9681-9687.	1.6	14
14	Î²â€Selective Câ€'H Arylation of Electronâ€Deficient Thiophenes, Pyrroles, and Furans. Israel Journal of Chemistry, 2020, 60, 416-418.	1.0	12
15	Ligand-Enabled Pd(II)-Catalyzed C(sp³)â€"H Lactonization Using Molecular Oxygen as Oxidant. Organic Letters, 2020, 22, 3960-3963.	2.4	38
16	metaâ€Selective Câ€'H Arylation of Fluoroarenes and Simple Arenes. Angewandte Chemie - International Edition, 2020, 59, 13831-13835.	7.2	50
17	meta â€Selective Câ€'H Arylation of Fluoroarenes and Simple Arenes. Angewandte Chemie, 2020, 132, 13935-13939.	1.6	13
18	In Praise of Remarkably Powerful Centamolecular Therapeutic Agents. ACS Medicinal Chemistry Letters, 2019, 10, 1094-1097.	1.3	8

#	Article	IF	Citations
19	Anti-Markovnikov Hydroamination of Unactivated Alkenes with Primary Alkyl Amines. Journal of the American Chemical Society, 2019, 141, 16590-16594.	6.6	81
20	meta Câ€“H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity. Journal of the American Chemical Society, 2019, 141, 14870-14877.	6.6	70
21	Hemilabile Benzyl Ether Enables Î³-C(sp³)â€“H Carbonylation and Olefination of Alcohols. Journal of the American Chemical Society, 2019, 141, 15494-15497.	6.6	44
22	Manganese-Catalyzed Desaturation of N-Acyl Amines and Ethers. ACS Catalysis, 2019, 9, 9513-9517.	5.5	33
23	Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126604.	1.0	10
24	Catalytic Ring Expansions of Cyclic Alcohols Enabled by Proton-Coupled Electron Transfer. Journal of the American Chemical Society, 2019, 141, 8752-8757.	6.6	85
25	Ni-Catalyzed Carbonâ€“Carbon Bond-Forming Reductive Amination. Journal of the American Chemical Society, 2018, 140, 2292-2300.	6.6	81
26	Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. Journal of Medicinal Chemistry, 2018, 61, 681-694.	2.9	23
27	Selective Câ^'H Halogenation with a Highly Fluorinated Manganese Porphyrin. Angewandte Chemie - International Edition, 2018, 57, 1251-1255.	7.2	72
28	Overcoming the Limitations of Î³- and Î´-Câ€“H Arylation of Amines through Ligand Development. Journal of the American Chemical Society, 2018, 140, 17884-17894.	6.6	156
29	Factor XIa Inhibitors as New Anticoagulants. Journal of Medicinal Chemistry, 2018, 61, 7425-7447.	2.9	44
30	Decarboxylative alkylation for site-selective bioconjugation of native proteins via oxidation potentials. Nature Chemistry, 2018, 10, 205-211.	6.6	272
31	Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode. Journal of Medicinal Chemistry, 2017, 60, 1417-1431.	2.9	25
32	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212). Journal of Medicinal Chemistry, 2017, 60, 9703-9723.	2.9	45
33	Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3833-3839.	1.0	19
34	Abstract TMP117: Preclinical and Early Clinical Characterization of a Parenterally Administered Direct Factor XIa Inhibitor. Stroke, 2017, 48, .	1.0	4
35	Supply and Demand of Chemists in the United States. ACS Symposium Series, 2015, , 15-33.	0.5	3
36	Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2013, 56, 9586-9600.	2.9	10

#	Article	IF	Citations
37	Solid Phase Synthesis of 1,5-Diarylpyrazole-4-carboxamides: Discovery of Antagonists of the CB-1 Receptor. ACS Combinatorial Science, 2012, 14, 197-204.	3.8	11
38	Cannabinoid CB1 receptor ligand binding and function examined through mutagenesis studies of F200 and S383. European Journal of Pharmacology, 2011, 651, 9-17.	1.7	8
39	Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6856-6860.	1.0	4
40	Identification of potent 11mer Glucagon-Like Peptide-1 Receptor agonist peptides with novel C-terminal amino acids: Homohomophenylalanine analogs. Peptides, 2010, 31, 950-955.	1.2	17
41	Exploration of structureâ€“activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis. Peptides, 2010, 31, 1353-1360.	1.2	8
42	Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5872-5876.	1.0	18
43	Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity. Journal of Medicinal Chemistry, 2009, 52, 7788-7799.	2.9	61
44	Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 474-478.	1.0	13
45	Design and synthesis of tetrazole-based growth hormone secretagogue: The SAR studies of the O-benzyl serine side chain. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1825-1829.	1.0	15
46	(d)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: Synthesis and incorporation into the growth hormone secretagogues. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4072-4074.	1.0	13
47	Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2007, 35, 795-805.	1.7	18
48	Discovery of a Tetrazole-Based Growth Hormone Secretagogue:â€‰ 4-(Hydroxybutyl)carbamic Acid 2-{5-[1-(2-Amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl Ester (BMS-317180). Journal of Medicinal Chemistry, 2007, 50, 5890-5893.	2.9	26
49	Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3978-3982.	1.0	33
50	Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3511-3515.	1.0	127
51	Synthesis of triazolopyridines and triazolopyrimidines using a modified Mitsunobu reaction. Arkivoc, 2007, 2007, 132-147.	0.3	15
52	Dual Angiotensin II and Endothelin A Receptor Antagonists:â€‰ Synthesis of 2â€˜-Substituted N-3-Isoxazolyl Biphenylsulfonamides with Improved Potency and Pharmacokinetics. Journal of Medicinal Chemistry, 2005, 48, 171-179.	2.9	76
53	Discovery of a Potent and Novel Motilin Agonist. Journal of Medicinal Chemistry, 2004, 47, 1704-1708.	2.9	37
54	Monochlorination of Electron-Rich Arylalkyl- and Heteroarylalkyl-Amines and Amino Acids Using Sulfuryl Chloride.. ChemInform, 2003, 34, no.	0.1	0

#	Article	IF	Citations
55	Molecular Structures of Human Factor Xa Complexed with Ketopiperazine Inhibitors:Â Preference for a Neutral Group in the S1 Pocket. Journal of Medicinal Chemistry, 2003, 46, 685-690.	2.9	121
56	Mono-Chlorination of Electron-Rich Arylalkyl- and Heteroarylalkyl-amines and Amino Acids Using Sulfuryl Chloride. Synthesis, 2003, 2003, 0403-0407.	1.2	10
57	Crystal Structures of Human Factor Xa Complexed with Potent Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 3226-3232.	2.9	130
58	Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2753-2758.	1.0	26
59	Design and Structureâ^'Activity Relationships of Potent and Selective Inhibitors of Blood Coagulation Factor Xa. Journal of Medicinal Chemistry, 1999, 42, 3557-3571.	2.9	41
60	Sulfonamidopyrrolidinone Factor Xa Inhibitors:Â Potency and Selectivity Enhancements via P-1 and P-4 Optimization. Journal of Medicinal Chemistry, 1999, 42, 3572-3587.	2.9	39
61	Affinity of fibroblast growth factors for Î²-cyclodextrin tetradecasulfate. Analytical Biochemistry, 1990, 185, 108-111.	1.1	39
62	Total synthesis and structural investigations of didemnins A, B, and C. Journal of the American Chemical Society, 1990, 112, 7659-7672.	6.6	139
63	Synthetic studies of didemnins. IV. Synthesis of the macrocycle. Tetrahedron Letters, 1989, 30, 3757-3760.	0.7	20
64	A Short, Stereocontrolled Synthesis of (â€")-Detoxinine. Heterocycles, 1988, 27, 2843.	0.4	29
65	Synthetic studies of didemnins. i. revision of the stereochemistry of the hydroxyisovalerylpropionyl (hip) unit.. Tetrahedron, 1986, 42, 5863-5868.	1.0	20